Denali therapeutics says paused enrollment in phase 1, phase 1b trials due to covid-19

Denali therapeutics provides pipeline and business update in response to the covid-19 pandemic.denali therapeutics - for ongoing dnl151 phase 1, phase 1b trials, enrollment of additional healthy volunteers & patients at higher doses has been paused due to covid-19.denali therapeutics - recruitment of additional patients in etv:ids program for hunter syndrome has been paused due to covid-19 pandemic.denali therapeutics inc - dnl310 phase 1/2 trial is on track to commence in q2 2020.denali therapeutics - enrollment of additional subjects in eif2b program for als (dnl343 phase 1 trial) has been paused due to covid-19 pandemic.denali therapeutics - has drug supplies to complete ongoing trials.denali therapeutics - additional drug substance supplies expected to be sufficient to support planned clinical trials well into 2021.denali therapeutics - on track to decide on next steps with dnl747 by mid-2020 together with its partner sanofi.denali therapeutics - with cash and investments of about $614 million at end of feb 2020, business operations expected to be funded at least through 2022.
DNLI Ratings Summary
DNLI Quant Ranking